Markets

NanoViricides Announces That NV-387 Successfully Demonstrated Strong Safety, Tolerability, And Toxicological Parameters In An Animal Model Study Involving Juvenile Mouse Pups

Oct 20, 2026 · 08:47 AM ET· updated 53m ago

This study is expected to pave the way for pediatric use of NV-387 in clinical trials in children possibly as young as 1 year old. Pediatric drugs for Ebola, Mpox, and Measles, as well as RSV - to name a few of the

Why It Matters

NanoViricides tested a new medicine on young mice and it seemed safe. This could mean they might test it on real children soon.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

NNVC1.35

+0.05 (+3.85%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.